JAK2 and leukemia: Our previous studies have shown that breeding of TEL-JAK2 transgenic mice on a Tcra-deficient background does not delay leukemia onset and incidence [25], although TEL-JAK2;Tcra−/− leukemic cells showed reduced RelA DNA-binding activity as compared to Tcra-proficient leukemic cells while maintaining a similar level of RelB DNA binding activity (Figure S5).